CombiGene
Jonas Ekblom is an experienced leader in the biopharmaceutical and gene therapy sectors, currently serving as the Chairman of the Board for CombiGene, Ziccum AB, and Oblique Therapeutics AB, alongside directorship roles at Moberg Pharma AB and Emplipharm AB. Between 2016 and 2023, Jonas held prominent positions as President and CEO of Promore Pharma AB and Chairman of EffRx Pharmaceuticals SA. Following the establishment of Pergamum AB, where Jonas acted as CEO and Board Director until its integration into Promore Pharma, the focus was on developing treatments for chronic wounds. Jonas possesses a strong academic background, including a Ph.D. in Experimental Neurology from Uppsala University and a Postdoctoral Fellowship in Molecular Pharmacology from the University of Southern California.
This person is not in any teams
CombiGene
CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com. CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme